Catalent appoints Shannon Trilli to strengthen its corporate responsibility initiatives
Will coordinate and organize the company’s existing initiatives in sustainability and maximizing social impact, and its employee-driven community programs.
Catalent Pharma Solutions has appointed Ms. Shannon Trilli in the newly created role of Director of Corporate Responsibility.
In her post, Ms Trilli will be responsible for implementing Catalent’s global corporate responsibility strategy. She will strengthen Catalent’s efforts in this area, which will continue to be led by its Corporate Responsibility Council, composed of senior Catalent leaders from multiple functions. Ms Trilli will coordinate and organize Catalent’s existing initiatives in sustainability and maximizing social impact, and its employee-driven community programs. She will also lead Catalent’s activities in establishing additional programs, including the matching of gifts and strategic volunteer initiatives, and the expansion of the organization’s philanthropic and partnership portfolio.
Before joining Catalent, she served as the Director of Corporate Responsibility at S&P Global, a leading provider of transparent and independent ratings, benchmarks, analytics and data to capital and commodity markets worldwide.
Prior to S&P Global, Ms Trilli acted as the Director of Global Health for the United Methodist Committee on Relief (UMCOR). There, she designed, scaled and led UMCOR's Signature Health Program to provide funding and technical support to community based health organizations. She also led its $75 million "Imagine No Malaria" program in sub-Saharan Africa, with partners such as the U.N. Foundation and The Global Fund.
Ms Trilli has also served as a micro-enterprise development Peace Corps volunteer in Bolivia, and early in her career, was the manager of Global Employee Programs for the Contributions and Community Relations unit of The McGraw-Hill Companies.
"In addition to more deeply engaging our communities and demonstrating Catalent's commitment to and improving health and the environment, Shannon’s appointment and implementation of the corporate responsibility strategy will help us more meaningfully connect to employees, customers, and stakeholders,” commented Alessandro Maselli, Catalent’s Senior Vice President of Global Operations. He added, “In her new role, she will help us effectively communicate how Catalent’s capabilities and values result in positive social and business impacts, both in our local communities and across the globe."
Ms Trilli earned a bachelor's in government from the University of Texas in Austin, and a master's degree in public administration from New York University.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance